Scholarlink

Objective <p>Radioactive iodine (RAI) therapy is one of the most widely used and relatively safe treatments for Graves’ disease (GD). However, its effects on liver function tests (LFTs) remain incompletely understood. This study aimed to evaluate early changes in LFTs following RAI therapy and to identify potential risk factors.</p> Results <p>We conducted a retrospective review of 122 patients with GD who received RAI therapy at our department between January 2019 and July 2020. Following RAI treatment, significant changes in liver biochemical parameters were observed: levels of total protein (TP), albumin (ALB), globulin (GLO), direct bilirubin (DBIL), and gamma-glutamyl transpeptidase (GGT) increased, while total bilirubin (TBIL), indirect bilirubin (IBIL), and aspartate aminotransferase (AST) decreased. Our findings suggest that RAI therapy is associated with new, transient abnormalities in liver biochemical parameters in over a quarter of patients, involving alterations in ALB, DBIL, AST, alkaline phosphatase (ALP), or combinations of these markers. Multivariate analysis revealed that younger age and higher RAI dosage were independent predictors of liver function test abnormalities following treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early effects of radioactive iodine (I-131) therapy on liver function in patients with Graves’ disease: a 48-h analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月27日

查看全文
  • Rui-Ting Hu,
  • Bin Li

摘要

Objective

Radioactive iodine (RAI) therapy is one of the most widely used and relatively safe treatments for Graves’ disease (GD). However, its effects on liver function tests (LFTs) remain incompletely understood. This study aimed to evaluate early changes in LFTs following RAI therapy and to identify potential risk factors.

Results

We conducted a retrospective review of 122 patients with GD who received RAI therapy at our department between January 2019 and July 2020. Following RAI treatment, significant changes in liver biochemical parameters were observed: levels of total protein (TP), albumin (ALB), globulin (GLO), direct bilirubin (DBIL), and gamma-glutamyl transpeptidase (GGT) increased, while total bilirubin (TBIL), indirect bilirubin (IBIL), and aspartate aminotransferase (AST) decreased. Our findings suggest that RAI therapy is associated with new, transient abnormalities in liver biochemical parameters in over a quarter of patients, involving alterations in ALB, DBIL, AST, alkaline phosphatase (ALP), or combinations of these markers. Multivariate analysis revealed that younger age and higher RAI dosage were independent predictors of liver function test abnormalities following treatment.